Osteogenic effects of flavonoid aglycones from an osteoprotective fraction of Drynaria fortunei--an in vitro efficacy study.

Drynaria fortunei (Kunze) J. Sm. is a traditional Chinese herb used for the treatment of osteoporosis and other bone metabolic disorders. Previous studies demonstrated that "small polar active fraction in Drynaria fortunei (SDF)"exerted osteoprotective effects in ovariectomized (OVX) mice. This study aims to investigate the constituents in SDF and systemically evaluate their osteogenic effects in vitro. Five flavonoid aglycones, naringenin, kurarinone, kushennol F, xanthogalenol, and sophoraflavanone G were identified in SDF. All the compounds did not show effects on proliferation of osteoblastic UMR 106 cells at the concentrations of 0.1-1000 nM, but significantly increased the ALP activity of the cells at most of the concentrations from 10 nm to 1000 nM. Xanthogalenol at the concentration of 100 nM significantly increased concentration of acid-solubilized calcium. ICI 182,780, antagonist of estrogen receptor (ER), diminished the effect of kushennol F on ALP activity and the effect of xanthogalenol on acid-solubilized calcium. In conclusion, flavonoid aglycones in SDF could promote differentiation and mineralization of osteoblastic UMR 106 cells in vitro, which was explained by activation of ER signaling pathway. This study provides scientific evidences for the conduction of in vivo experiments to confirm potential effects of flavonoid aglycones on preventing OVX-induced osteoporosis.